Tyra Biosciences (NASDAQ:TYRA) Announces Earnings Results

Tyra Biosciences (NASDAQ:TYRA) announced its quarterly earnings results on Tuesday. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.07), FiscalAI reports.

Tyra Biosciences Stock Performance

NASDAQ TYRA opened at $20.97 on Thursday. Tyra Biosciences has a fifty-two week low of $14.67 and a fifty-two week high of $40.65. The stock has a 50 day simple moving average of $21.95 and a two-hundred day simple moving average of $29.49. The stock has a market cap of $1.25 billion, a P/E ratio of -7.94 and a beta of 0.65.

Analysts Set New Price Targets

Several brokerages have recently issued reports on TYRA. William Blair upgraded shares of Tyra Biosciences to a “strong-buy” rating in a report on Wednesday, September 23rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Tyra Biosciences in a report on Thursday, September 10th. Raymond James Financial reissued a “strong-buy” rating and set a $50.00 price target on shares of Tyra Biosciences in a research report on Tuesday, October 6th. HC Wainwright cut their price target on shares of Tyra Biosciences from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Piper Sandler reissued an “overweight” rating and issued a $56.00 price target on shares of Tyra Biosciences in a report on Tuesday, September 8th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $47.40.

About Tyra Biosciences

Tyra Biosciences, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges. The company’s pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers.